Health Care/Hospital
Gryphon Investors Announces Acquisition of Metagenics
Investment Will Support Leading Global Nutritional Products Provider's Mission to Improve Health Outcomes in Partnership with Healthcare Practitioners SAN FRANCISCO, Oct. 18, 2021 /PRNewswire/ -- Gryphon Investors ("Gryphon"), a leading middle-market private equity firm, today announced that it ...
Concord Medical Is Shortlisted for the "5G+Healthcare" Pilot Project
BEIJING, Oct. 18, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specializing in cancer care, research and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone ...
WuXi ATU Opens New Manufacturing Facility to Further Enhance Its CTDMO Services for Global Customers
PHILADELPHIA, Oct. 17, 2021 /PRNewswire/ -- WuXi Advanced Therapies Inc. (WuXi ATU) – a wholly owned subsidiary of WuXi AppTec – today announced the opening of its new process development and commercial manufacturing facility in Lin-gang, Shanghai. WuXi ATU is a leading Contract, Testing, Develop...
Concord Medical Files 2020 Annual Report on Form 20-F
BEIJING, Oct. 15, 2021 /PRNewswire/ -- Concord Medical Services Holdings
Limited ("Concord Medical" or the "Company") (NYSE: CCM
Neusoft Ranks Top in China Healthcare Security Informatization Market
SHENYANG, China, Oct. 15, 2021 /PRNewswire/ -- According to the Market Shares of Healthcare Security Information System ofChina 2020: Building a New Healthcare Security Information System recently released by International Data Corporation (IDC) for the first time, Neusoft Corporation ("Neusoft",...
CellOrigin secured a new round of investment for developing its globally proprietary iPSC-CAR-Macrophage technology platform
HANGZHOU, China, Oct. 15, 2021 /PRNewswire/ -- On Oct. 11th, 2021, CellOrigin Inc. released data about its second generation of iPSC-CAR-Macrophage which has a genetically integrated secondary signal to confer controlled CAR-iMac polarization, in the 5th International Conference of IGC China, 202...
Akeso is Rapidly Advancing The Phase II Clinical Trial of IL-4R Monoclonal Antibody (AK120) for the Treatment of Atopic Dermatitis and Asthma
HONG KONG, Oct. 15, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that the Company's self-developed innovative drug candidate, IL-4R monoclonal antibody (AK120), was approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration ofthe People...
Week's Top Stories
Most Reposted
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
[Picked up by 310 media titles]
2026-10-13 10:00Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 275 media titles]
2026-10-09 13:21DayOne Upsizes Malaysia Financing to US$7.2 Billion; Total Billings Surpass 1GW and Bookings Reach 2.3GW
[Picked up by 265 media titles]
2026-10-14 18:01Nuix Neo Generative AI Framework
[Picked up by 262 media titles]
2026-10-08 08:02